➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Johnson and Johnson
McKinsey
Mallinckrodt
Merck

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

Claims for Patent: 8,808,750


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,808,750
Title:Microporous zirconium silicate for the treatment of hyperkalemia
Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
Inventor(s): Keyser; Donald Jeffrey (Southlake, TX), Guillem; Alvaro F. (Lantana, TX)
Assignee: ZS Pharma, Inc. (Coppell, TX)
Application Number:14/036,489
Patent Claims: 1. A method for treatment of hyperkalemia comprising administering a particulate pharmaceutical composition comprising a zirconium silicate of formula (I): A.sub.pM.sub.xZr.sub.1-xSi.sub.nGe.sub.yO.sub.m (I) in ZS-9 form, where A is a potassium ion, sodium ion, rubidium ion, cesium ion, calcium ion, magnesium ion, hydronium ion or mixtures thereof, M is at least one framework metal, wherein the framework metal is hafnium (4+), tin (4+), niobium (5+), titanium (4+), cerium (4+), germanium (4+), praseodymium (4+), terbium (4+) or mixtures thereof, "p" has a value from about 1 to about 20, "x" has a value from 0 to less than 1, "n" has a value from 1 to about 12, "y" has a value from 0 to about 12, "m" has a value from about 3 to about 36 and 1<n +y<12, wherein the particles exhibit a uniform microporous structure and a median particle size of greater than 3 microns and less than 7% of the particles in the composition have a diameter less than 3 microns, and the composition exhibits a sodium content below 12% by weight.

2. The method of claim 1, wherein the sodium content is less than 6% by weight.

3. The method of claim 1, wherein the sodium content is between 0.05 to 3% by weight.

4. The method of claim 1, wherein the sodium content is less than 0.01% by weight.

5. The method of claim 1, wherein less than 3% of the particles in the composition have a diameter less than 3 microns.

6. The method of claim 1, wherein less than 2.5% of the particles in the composition have a diameter less than 3 microns.

7. The method of claim 1, wherein the composition exhibits a median particle size of greater than 3 microns and less than 2% of the particles in the composition have a diameter less than 3 microns.

8. The method of claim 1, wherein the median particle size ranges from 5 to 1000 microns.

9. The method of claim 1, wherein the composition exhibits a particle size in the range of about 5 to about 200 microns.

10. The method of claim 1, wherein the median particle size ranges from 20 to 100 microns.

11. The method of claim 1, wherein the composition exhibits an x-ray powder diffraction pattern generated using a copper K-alpha radiation source comprising: a first peak at 2 theta corresponding to a first d-spacing within the range of 2.7-3.5angstroms, and a second peak at 2 theta corresponding to a second d-spacing within the range of 5.3-6.1 angstroms.

12. The method of claim 11, wherein the x-ray powder diffraction pattern further comprises: a third peak at 2 theta corresponding to a third d-spacing within the range of 5.9-6.7 angstroms, a fourth peak at 2 theta corresponding to a fourth d-spacing within the range of 2.0-2.8 angstroms, and a fifth peak at 2 theta corresponding to a fifth d-spacing within the range of 1.6-2.4 angstroms, the third, fourth, and fifth peaks each have intensity values that are lower than the first and second intensity values.

13. The method of claim 11, wherein the composition further exhibits an x-ray powder diffraction pattern generated using a copper K-alpha radiation source with at least a third peak at 2 theta corresponding to a third d-spacing within the range of 5.9-6.7 angstroms, and a fourth peak at 2 theta corresponding to a fourth d-spacing within the range of 2.0-2.8 angstroms, the third peak having the third greatest relative intensity within the diffraction pattern, and the fourth peak having the fourth greatest relative intensity within the diffraction pattern.

14. The method of claim 13, wherein the composition further exhibits at least a fifth peak at 2 theta corresponding to a fifth d-spacing within the range of 1.6 to 2.4 angstroms, the fifth peak having the fifth greatest relative intensity within the diffraction pattern.

15. The method of claim 1, wherein the patient is suffering from acute hyperkalemia.

16. The method of claim 15, wherein the patient is administered a dose of approximately 0.7 to 1,500 mg/Kg/day.

17. The method of claim 15, wherein the patient is administered a dose of approximately 500 to 1,000 mg/Kg/day.

18. The method of claim 15, wherein the patient is administered a dose of approximately 700 mg/Kg/day.

19. The method of claim 1, wherein the patient is suffering from chronic hyperkalemia.

20. The method of claim 19, wherein the patient is administered a dose of approximately 0.25 to 100 mg/Kg/day.

21. The method of claim 19, wherein the patient is administered a dose of approximately 50 mg/Kg/day.

22. The method of claim 1, wherein the patient is at risk for congestive heart failure.

23. The method of claim 1, wherein the patient has edema from elevated sodium levels.

24. The method of claim 1, wherein the FTIR spectra of the composition does not include absorption peaks at approximately 764 cm.sup.-1.

25. The method of claim 1, wherein the composition does not indicate peaks at 2-theta values of 7.5, 32, or 42.5 angstroms when the x-ray diffraction spectrum is generated using a copper K-alpha radiation source.

26. The method of claim 1, wherein the composition administered is a powered composition.

27. The method of claim 1, wherein the composition is formed into a shaped article.

28. The method of claim 27, wherein the shaped article is a tablet.

29. A method for treatment of hyperkalemia comprising administering to a subject in need thereof an effective amount of a powdered composition comprising ZS-9 having an x-ray diffraction pattern of: TABLE-US-00008 d(.ANG.) 5.9-6.7 5.3-6.1 2.7-3.5 2.0-2.8 1.6-2.4.

wherein the ZS-9 exhibits a uniform microporous structure and the composition exhibits a median particle size of greater than 3 microns and less than 3% of the particles in the composition have a diameter less than 3 microns, and the composition exhibits a sodium content below 12% by weight.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Colorcon
Medtronic
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.